Trial Information

Empirical Antifungal Treatment in Neutropenic Patients Stratified by Risk: Prospective Validation of an Algorithm Based on the D-index

Neutropenia is a major risk factor for invasive fungal infections, particularly those caused
by moulds, such as Aspergillus spp., Fusarium spp. and the Zygomycetes. Among neutropenic
patients, these invasive mould infections (IMI) occur almost exclusively in patients with
profound neutropenia (<100 neutrophils/mm3) lasting more than 10-15 days [1-3]. Empiric
antifungal therapy is considered standard of care in patients with persistent or recurrent
fever and neutropenia. However using fever as the sole criterion for starting empiric
therapy, a significant number of patients will receive antifungal therapy unnecessarily,
particularly among recipients of fluconazole prophylaxis, because persistent fever in these
patients is commonly due to various factors, such as uncontrolled occult bacterial
infection, viral infection, drug fever and others [4].

An alternative to empiric antifungal therapy is the preemptive treatment. In this strategy,
other markers (such as serology, radiology and clinical data) are added to persistent fever
[5,6]. One problem of such strategy is that the biomarkers currently in use (galactomannan
[GM], 1,3-beta-D-glucan and PCR) have high sensitivity. If one of these markers is used to
trigger the start of antifungal therapy, still a considerable number of patients will use
antifungal agents unnecessarily. However, a positive biomarker early in the course of
neutropenia most likely represents a false-positive result. By contrast, a positive
biomarker test late in the course of neutropenia is more likely to be a true positive. A
problem is that no cutoff value of duration of neutropenia is validated to help clinicians
to identify these 2 possibilities.

A clinical parameter that evaluated the dynamics of neutropenia, combining intensity and
duration, could be a good tool to identify patients at high risk for IMI. This tool could be
used to stratify patients, helping clinicians to select appropriate candidates for early
antifungal therapy (empiric or preemptive) in persistently febrile neutropenic patients. We
developed an index (called D-index) that uses data from white blood cell counts (WBC), and
combines intensity and duration of neutropenia. This index was tested in patients with acute
myeloid leukemia, and showed a good discriminatory performance in identifying patients with
IMI and without IMI. A cutoff was derived, and showed good sensitivity, specificity and a
very high negative predictive value (97 to 99%) [7]. The high negative predictive value of
this index is very similar to that obtained with GM and 1,3-beta-D-glucan in febrile
neutropenic patients [8,9]. With this regard, the D-index could be of help to assess the
pre-test probability of IMI and help to interpret the results of positive serum GM and / or
1,3-beta-D-glucan: patients with low values of D-index would be best interpreted as having
false-positive results of these tests. Similarly, positive biomarkers in the presence of a
high D-index would be more likely to be true positives, since the combination of different
tests may increase their positive predictive value.

This is a prospective cohort study. The study will be submitted to the IRB and written
informed consent will be obtained from all participants.

Patients aged ≥ 18 years are eligible if they have acute leukemia, myelodysplasia or other
underlying hematologic malignancy receiving chemotherapy with an expected duration of
neutropenia (<500/mm3) >10 days. This includes allogeneic (but not autologous) hematopoietic
stem cell transplantation. Patients with past history of IMI will be excluded, since for
these patients secondary prophylaxis is advised.

Patients will be enrolled at initiation of chemotherapy and no later than 48h from the first
day of neutropenia. The same patient will be able to be enrolled more than once, but if he
develops IMI, he will be no longer eligible for a subsequent inclusion. All patients will
receive antimicrobial prophylaxis with fluconazole (400mg daily). Chest imaging (X-ray or CT
scan) will be performed at the enrollment. During the period of neutropenia induced by
chemotherapy/ conditioning regimen, patients will be surveyed for the development of fever
and will have the D-index calculated day by day. At the time of febrile neutropenia, at
least 2 blood cultures will be collected. Other microbiologic exams will be obtained if
clinically indicated. The patients will then receive a broad-spectrum β-lactam antibiotic
(cefepime). Vancomycin will be added for patients who have clinically suspicion of
catheter-related infection or a blood culture yielding Gram-positive bacteria not yet
identified. Serum will be obtained 3 times a week for Aspergillus GM assay (Platelia
Aspergillus; Bio-Rad) and Aspergillus sp. PCR (in-house real time qualitative and
quantitative PCR). A positive GM will be defined as an index ≥ 0.5.

In case of persistent fever or a new fever, blood cultures will be collected and CT scans of
the chest and the sinuses will be performed. Results of GM will be checked and the patients
will be stratified according to the D-index as high, moderate or low risk for IMI. Based on
this analysis, antifungal therapy (caspofungin 70 mg day 1 and 50 mg/d thereafter) will be
started. In high risk patients (D index ≥ 5,800), the trigger for anti mold treatment will
be the presence of any image on CT scan or any positive GM. In the moderate risk (D-index
between 3,000 and 5,800), the trigger will be the presence of persistence of a positive GM
in consecutive tests. In this stratum, chest CT scan will be defined as indicative of
antifungal initiation only in the presence of one of the following: nodules > 1 cm, with or
without halo sign, wedge-shaped images, or cavitation. For low-risk patients (D-index
<3,000), antifungal treatment will be started only in the persistence of positive GM result
in consecutive tests. In situations in which antifungal treatment is not started,
reassessment of these parameters will be made at least twice a week with the evaluation of
the D-index and biomarkers, and once a week with CT scans. In patients with lung
infiltrates, a bronchoalveolar lavage (BAL) will be taken, provided the patient is not
hypoxemic or severely thrombocytopenic and refractory to platelet transfusions. In the
presence of findings in sinuses CT scans suggestive of sinusitis, nasal endoscopy will be
performed. BAL and sinus aspiration samples will be processed for direct examination,
culture, GM and Aspergillus PCR. Other diagnostic procedures will be performed when
clinically indicated. Autopsy will be performed in all fatal cases after family
authorization. Invasive fungal infection will be classified according to the Revised
Definitions from the European Organization for Research and Treatment of Cancer/Invasive
Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious
Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [10].

To assess the performance of risk stratification based on the D-index, the overall use of
antifungal treatment (al well as stratified by D-index) will be recorded, and reported by
descriptive statistics. The outcome of each risk stratus (low, moderate and high) will be
compared regarding: incidence of suspected and documented mold infection, use of anti mold
therapy, duration of hospitalization and death rate. In addition, the proportion of patients
receiving early antifungal treatment will be compared with empiric antifungal use in a
historical matched-control cohort. Patients from the 2 cohorts will be compared using
propensity score procedure. Propensity score analysis attempts to identify patients who are
similar except for their treatment. The analysis will be performed as follows: first, the
probability of any patient in the database to receive empiric antifungal therapy will be
estimated using a multivariate logistic regression model that incorporates baseline
characteristics, underlying diseases and co-morbidities. Next, we will match from the 2
cohorts patients with the nearest propensity score (the score generated by the multivariate
equation)[10].

Based on our database of ~2,000 episodes of febrile neutropenia, 36% of patients had
persistent fever between days 4 and 7 of antibiotics and would receive empiric antifungal
therapy. A total of 105 patients would be needed to demonstrate a 50% reduction in
antifungal use if we compared this cohort with a matched control historical cohort (alpha =
5%, beta = 20%).